MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET 2019-2028

Lifesciences | Diagnostic & Biotechnology

MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET 2019-2028

Market by Product, Application, Technology, End-user and Geography | Forecast 2019-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

A Triton Market Research report has determined that the molecular point of care diagnostics market in the Middle East and Africa is set to surge at CAGR of 13.75% during the projected period 2019-2028.



We provide additional customization based on your specific requirements. Request For Customization

The countries scrutinized in the Middle East and Africa market are:

           Turkey

           Saudi Arabia

           United Arab Emirates

           South Africa

           Rest of Middle East & Africa

Turkey has taken several initiatives to re-establish the crumbling healthcare system in the past few years. For instance, in order to avoid the problem of overcrowding in the hospitals run by the Social Security Fund, they were merged with the hospital run by the Health Ministry. Also, city hospitals, especially in the suburbs, are the latest development initiative to drive the modernization of Turkey's health sector.

The government aims to enhance the country's health standards by increasing the average hospital bed capacity. The country has been identified as the fastest rising infection rates across the world, partially owing to the increased testing capacity. Turkey is among the top 10 countries in the world, with the maximum number of COVID-19 tests carried out. These factors are likely to instigate the growth of the molecular point of care diagnostics market.

The Saudi Arabian healthcare system has developed rapidly in the past few years. This growth may be contributed by the country's increased wealth and the fact that healthcare quality is its high priority. Besides, free universal healthcare in the country will ensure fair access to the entire population. These factors will consequently help the market for the molecular point of diagnostics.

Mesa Biotech is a company that is engaged in designing, developing, manufacturing and marketing next-generation molecular diagnostic tests. Concerning the molecular point of care diagnostics, the company provides Accula System, which consists of a portable dock and specific test cassettes. The company also provides Accula Flu A/Flu B and the Accula RSV assay for the diagnosis of respiratory diseases.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET - SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. KEY INSIGHTS

2.2.1.   INCREASED GERIATRIC POPULATION REQUIRES MORE DIAGNOSTIC SERVICES

2.2.2.   OPPORTUNITIES FROM EMERGING COUNTRIES FOR THE MARKET

2.2.3.   HYBRIDIZATION OF AVAILABLE TECHNOLOGIES IS A PROMISING TREND

2.3. PORTER’S FIVE FORCE ANALYSIS

2.3.1.   THREAT OF NEW ENTRANTS

2.3.2.   THREAT OF SUBSTITUTE

2.3.3.   BARGAINING POWER OF SUPPLIERS

2.3.4.   BARGAINING POWER OF BUYERS

2.3.5.   THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. MARKET DRIVERS

2.6.1.   DEMAND FOR DIAGNOSING PRESENCE OF SARS COV-2

2.6.2.   INCREASING DEMAND FOR NON-INVASIVE DIAGNOSIS

2.6.3.   RISE IN THE NUMBER OF DISEASES

2.7. MARKET RESTRAINTS

2.7.1.   HIGH CAPITAL REQUIREMENT

2.8. MARKET OPPORTUNITIES

2.8.1.   SPENDING ON RESEARCH & DEVELOPMENT

2.8.2.   INNOVATIONS IN THE MARKET

2.9. MARKET CHALLENGES

2.9.1.   LACK OF HIGH COMPLEXITY TESTING CENTERS

3. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK – BY PRODUCT

3.1. ASSAYS

3.2. INSTRUMENTS

3.3. SOFTWARE

4. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY APPLICATION

4.1. INFECTIOUS DISEASE

4.1.1.   RESPIRATORY

4.1.2.   HOSPITAL-ACQUIRED INFECTIONS

4.1.3.   SEXUALLY-TRANSMITED INFECTIONS

4.1.4.   GASTROINTESTINAL INFECTIONS

4.2. ONCOLOGY

4.3. PRENATAL

4.4. OTHERS

5. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY TECHNOLOGY

5.1. POLYMERASE CHAIN REACTION

5.1.1.   REAL-TIME PCR (Q-PCR)

5.1.2.   DIGITAL PCR (D-PCR)

5.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY

5.3. OTHER

6. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY END-USER

6.1. HOSPITAL

6.2. CLINICS

6.3. DIAGNOSTIC CENTERS

6.4. OTHERS

7. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET – REGIONAL OUTLOOK

7.1. UNITED ARAB EMIRATES

7.2. TURKEY

7.3. SAUDI ARABIA

7.4. SOUTH AFRICA

7.5. REST OF MIDDLE EAST & AFRICA

8. COMPETITIVE LANDSCAPE

8.1. ABBOTT

8.2. ABACUS DIAGNOSTICA

8.3. BIOMERIEUX SA

8.4. BIOCARTIS

8.5. DANAHER

8.6. DIASORIN SPA

8.7. BIO-RAD LABORATORIES INC

8.8. F HOFFMANN-LA ROCHE LTD

8.9. LUMINEX CORPORATION

8.10. HOLOGIC INC

8.11. MESA BIOTECH

8.12. SPARTAN BIOSCIENCES INC

8.13. QUANTUMDX GROUP LTD

8.14. QUIDEL CORPORATION

8.15. QIAGEN

9. METHODOLOGY & SCOPE

9.1. RESEARCH SCOPE

9.2. SOURCES OF DATA

9.3. RESEARCH METHODOLOGY

List of table

TABLE 1: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)

TABLE 2: MARKET ATTRACTIVENESS INDEX

TABLE 3: VENDOR SCORECARD

TABLE 4: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)

TABLE 5: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)

TABLE 6: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)

TABLE 7: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)

TABLE 8: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)

TABLE 9: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)

TABLE 10: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)

List of Figures

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: COST COMPARISON BETWEEN LABORATORY, IMMUNOASSAY AND MOLECULAR POC DIAGNOSTIC TESTS

FIGURE 3: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)

FIGURE 4: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)

FIGURE 5: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)

FIGURE 6: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)

FIGURE 7: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)

FIGURE 8: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL-ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 9: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY-TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 10: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTROINTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 11: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)

FIGURE 12: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)

FIGURE 13: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 14: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)

FIGURE 15: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL-TIME PCR (Q-PCR), 2019-2028 (IN $ MILLION)

FIGURE 16: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR (D-PCR), 2019-2028 (IN $ MILLION)

FIGURE 17: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)

FIGURE 18: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)

FIGURE 19: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL, 2019-2028 (IN $ MILLION)

FIGURE 20: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)

FIGURE 21: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTERS, 2019-2028 (IN $ MILLION)

FIGURE 22: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 23: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2018 & 2028 (IN %)

FIGURE 24: UNITED ARAB EMIRATES MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 25: TURKEY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 26: SAUDI ARABIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 27: SOUTH AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 28: REST OF MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;